Progressive supranuclear paralysis with levodopa-induced dyskinesia

Close metadata

Recommended articles:

The association of single-nucleotide polymorphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):82-88

Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):15-22

Association of inflammation and chronic fatigue syndrome in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):79-87

Electric activity of the brain at early and late clinical stages of experimental modeling of Parkinson’s disease, an impact of hemantane. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):129-134

Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34

Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72

Clinical presentation and diagnosis of Parkinson’s disease in patients with schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99

Chronic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112

Progressive supranuclear palsy (PNP) is a neurodegenerative disease characterized by a combination of progressive akinetic-rigid syndrome, postural instability with frequent falls, supranuclear ophthalmoplegia, pseudobulbar syndrome and frontal dementia. The disease usually develops after the sixth decade of life, and has a progressive course. An own description of the clinical case of progressive supranuclear palsy in a 79-year-old patient with oromandibular hyperkinesis while taking levodopa is presented.

Keywords:

supranuclear palsy

Steele—Richardson—Olszewski syndrome

Parkinson’s disease

Authors:

Safin Sh.M.

Bashkir State Medical University

ORCID: 0000-0002-0100-6100

Derevyanko H.P.

Bashkir State Medical University

Blinova N.M.

Bashkir State Medical University

Received:

09.04.2020

Accepted:

18.06.2020

List of references:

Artem’ev DV, Golubev VL, Yakhno NN. Progressiruyushchii nad»yadernyi paralich. In: Yakhno N.N., Shtul’mana D.R, red. T. 2. Bolezni nervnoi sistemy. M.: Meditsina; 2001. (In Russ.).
Mozolevsky YuV, Yakhno NN, Voznesenskaya TG, Kuuz RA. Progressive supranuclear palsy. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1980;80(3):67-72. (In Russ.).
Steele JC. Progressive supranuclear palsy. Historical notes. J Neural Transm Suppl. 1994;42:3-14.
Steele J, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous system degeneration involving brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333-359. https://doi.org/10.1001/archneur.1964.00460160003001
Brusa A, Mancardi GL, Buigiani O. Progressive supranuclear palsy 1979: an overview. Ital J Neurol Sci. 1980;4:205-222. https://doi.org/10.1007/bf02336701
Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology. 1988;38(7):1031-1034. https://doi.org/10.1212/wnl.38.7.1031
Kawashima M, Miyake M, Kusumi M, et al. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord. 2004;19(10):1239-1240. https://doi.org/10.1002/mds.20149
Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771-1775. https://doi.org/10.1016/s0140-6736(99)04137-9
Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Mov Disord. 2011;26(6):1083-1095. https://doi.org/10.1002/mds.23713
De Bruin VM, Lees AJ. Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases. Mov Disord. 1994;9(4):381-389. https://doi.org/10.1002/mds.870090402
Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology. 1998;50(6):1637-1647. https://doi.org/10.1212/wnl.50.6.1637
Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016;22:29-33. https://doi.org/10.1016/j.parkreldis.2015.09.020
Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394-400. https://doi.org/10.1097/WCO.0b013e32833be924
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9. https://doi.org/10.1212/WNL.47.1.1
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32:853-864. https://doi.org/10.1002/mds.26987
McFarland NR. Diagnostic Approach to Atypical Parkinsonian Syndromes. Continuum (Minneap Minn). 2016;22(4 Movement Disorders):1117-1142. https://doi.org/10.1212/CON.0000000000000348
Ponomarev VV. Neirodegenerativnye zabolevaniya. SPb.: Foliant; 2013. (In Russ.).
Fedotova EYu, Chechetkin AO, Ivanova-Smolenskaya IA, Illarioshkin SN. A case of progressive supranuclear palsy with corticobasal syndrome. Nervous Diseases. 2009;2:38-43. (In Russ.).
Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005;64(12):2050-2055. https://doi.org/10.1212/01.WNL.0000165960.04422.D0
Gröschel K, Kastrup A, Litvan I, Schulz JB. Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology. 2006;66(6):949-950. https://doi.org/10.1212/01.wnl.0000203342.77115.bf
Righini A, Antonini A, De Notaris R, et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol. 2004;25(6):927-932.
Josephs KA. Frontotemporal lobar degeneration. Neurol Clin. 2007;25(3):683-696. https://doi.org/10.1016/j.ncl.2007.03.005
Adachi M, Kawanami T, Ohshima H, et al. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci. 2004;3(3):125-132. https://doi.org/10.2463/mrms.3.125
Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1):5-12. https://doi.org/10.1136/jnnp.2008.157370
Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis. 2013;36(1):145-153. https://doi.org/10.3233/JAD-130032
Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1997;62(4):352-356. https://doi.org/10.1136/jnnp.62.4.352
Stamelou M, Höglinger G. A Review of Treatment Options for Progressive Supranuclear Palsy. CNS Drugs. 2016;30(7):629-636. https://doi.org/10.1007/s40263-016-0347-2
Scelzo E, Lozano AM, Hamani C, et al. Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. J Neurol Neurosurg Psychiatry. 2017;88(7):613-616. https://doi.org/10.1136/jnnp-2016-315192
Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130(Pt 6):1552-1565. https://doi.org/10.1093/brain/awm032
Sale P, Castiglioni D, De Pandis MF, et al. The Lee Silverman Voice Treatment (LSVT) speech therapy in progressive supranuclear palsy. Eur J Phys Rehabil Med. 2015;51(5):569-574.
Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266. https://doi.org/10.1212/NXI.0000000000000266
O’Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(Pt 5):1362-1372. https://doi.org/10.1093/brain/awn065
Testa D, Monza D, Ferrarini M, et al. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci. 2001;22(3):247-251. https://doi.org/10.1007/s100720100021
dell’Aquila C, Zoccolella S, Cardinali V, et al. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism Relat Disord. 2013;19(11):980-985. https://doi.org/10.1016/j.parkreldis.2013.06.014
Pekmezović T, Ječmenica-Lukić M, Petrović I, et al. Quality of life in patients with progressive supranuclear palsy: one-year follow-up. J Neurol. 2015;262(9):2042-2048. https://doi.org/10.1007/s00415-015-7815-3
Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(5):402-411. https://doi.org/10.1136/jnnp-2016-314956

Close metadata